| Not Yet Recruiting | Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at Hi NCT07499999 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies NCT07340541 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Recruiting | PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) NCT07222215 | Kristina A. Fanucci | Phase 2 |
| Recruiting | Breast Re-irradiation After Second Ipsilateral Lumpectomy NCT06867484 | Youssef Zeidan | N/A |
| Recruiting | Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer NCT06525766 | Mayo Clinic | Phase 2 |
| Recruiting | Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt) NCT06150898 | Jules Bordet Institute | Phase 2 |
| Not Yet Recruiting | Early Changes in Metabolic Health in Breast Cancer Patients Initiating Endocrine Therapy NCT06623903 | Aarhus University Hospital | — |
| Enrolling By Invitation | Evaluation of a Novel Technique for the Discovery of New, Tumor-specific Targets for the Deployment of Innovat NCT06629233 | University Ghent | N/A |
| Recruiting | The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer NCT06439693 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | The FEMA Study: Feasibility of Exercise in Patients With Metastatic Breast Cancer and Adiposity NCT06343987 | Aarhus University Hospital | N/A |
| Recruiting | Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metas NCT06062498 | Northwestern University | Phase 2 |
| Recruiting | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer NCT05020860 | Baylor Breast Care Center | Phase 2 |
| Recruiting | (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer NCT05607004 | Atossa Therapeutics, Inc. | Phase 2 |
| Unknown | Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast NCT05076695 | Fudan University | Phase 2 |
| Completed | Electronic Medical Record-Based Nudge to Reduce SLNB NCT06006910 | University of Pittsburgh Medical Center | — |
| Terminated | Biology Guided Therapy for Breast Cancer for ER Positive NCT04965688 | Inova Health Care Services | Phase 2 |
| Terminated | [18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial NCT04727632 | University of Utah | EARLY_Phase 1 |
| Terminated | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) NCT04504916 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Unknown | Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study) NCT04571437 | Cairo University | Phase 2 |
| Withdrawn | COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Canc NCT04038489 | University of Virginia | Phase 2 |
| Completed | A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer NCT03962647 | Vanderbilt-Ingram Cancer Center | EARLY_Phase 1 |
| Completed | Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer NCT03719495 | Duke University | — |
| Active Not Recruiting | Personalised Disease Monitoring in Metastatic Breast Cancer NCT04597580 | The Christie NHS Foundation Trust | — |
| Unknown | Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative M NCT03633331 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Completed | Pre-operative Immunotherapy Combination Strategies in Breast Cancer NCT03395899 | Queen Mary University of London | Phase 2 |
| Completed | Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Brea NCT03250676 | Eisai Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer NCT02947685 | Alliance Foundation Trials, LLC. | Phase 3 |
| Completed | TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer NCT02988986 | The Methodist Hospital Research Institute | Phase 2 |
| Unknown | The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer NCT03768479 | First Affiliated Hospital Xi'an Jiaotong University | N/A |
| Completed | Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breas NCT02668666 | Oana Danciu, MD | Phase 2 |
| Active Not Recruiting | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca NCT02957968 | Virginia Commonwealth University | Phase 2 |
| Terminated | A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older NCT02823262 | Beth Israel Deaconess Medical Center | N/A |
| Completed | Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer NCT02820961 | Syndax Pharmaceuticals | Phase 1 |
| Completed | Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Horm NCT02186470 | Ohio State University Comprehensive Cancer Center | N/A |
| Active Not Recruiting | A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers NCT02238808 | AHS Cancer Control Alberta | Phase 2 |
| Completed | [18F]FES PET/CT in Endocrine Refractory Breast Cancer NCT02409316 | University of Pennsylvania | Phase 2 |
| Completed | Patterns of Prescribing and Monitoring of Palbociclib NCT03285568 | Rush University Medical Center | — |
| Terminated | Phase II Study of Everolimus Beyond Progression NCT02269670 | Emory University | Phase 2 |
| Terminated | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kid NCT02273752 | Emory University | Phase 2 |
| Completed | Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metast NCT02015559 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors NCT02235051 | City of Hope Medical Center | N/A |
| Terminated | Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy NCT02414776 | Western Regional Medical Center | Phase 1 |
| Active Not Recruiting | Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer NCT01992952 | Velindre NHS Trust | Phase 1 / Phase 2 |
| Active Not Recruiting | Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing NCT01953588 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Completed | A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer NCT02216786 | Queen Mary University of London | Phase 2 |
| Active Not Recruiting | REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Ther NCT01984138 | Polly A. Niravath, MD | Phase 2 |
| Active Not Recruiting | FDG PET/CT in Breast Cancer Bone Mets NCT01996046 | University of Pennsylvania | — |
| Active Not Recruiting | A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) NCT01824836 | ECOG-ACRIN Cancer Research Group | N/A |
| Active Not Recruiting | BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer NCT01791478 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Terminated | A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopaus NCT02000375 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Unknown | Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor NCT01765049 | Seoul National University Hospital | — |
| Terminated | Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid NCT01409811 | City of Hope Medical Center | N/A |
| Completed | BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Ca NCT01339442 | Washington University School of Medicine | Phase 1 |
| Terminated | Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive NCT01368263 | Washington University School of Medicine | Phase 2 |
| Terminated | Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer NCT01394211 | University of Arizona | Phase 2 |
| Completed | Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer NCT01385280 | University of Arizona | N/A |
| Completed | Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms NCT01194440 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Terminated | RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III NCT01208441 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the P NCT01219699 | Novartis Pharmaceuticals | Phase 1 |
| Withdrawn | Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer NCT01100489 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ NCT00952731 | Northwestern University | Phase 2 |
| Completed | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer NCT01037790 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Completed | Breast Cancer Diet Intervention Study NCT03886389 | Helse Stavanger HF | N/A |
| Completed | F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormon NCT00602043 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With NCT00676663 | Syndax Pharmaceuticals | Phase 2 |
| Completed | Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanopart NCT00407888 | University of Washington | Phase 2 |
| Terminated | Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA B NCT00194792 | University of Washington | Phase 2 |
| Completed | Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer NCT00082810 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating NCT00066690 | ETOP IBCSG Partners Foundation | Phase 3 |
| Completed | Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer T NCT00194779 | University of Washington | Phase 2 |
| Completed | Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cance NCT00057941 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in NCT00003199 | Fred Hutchinson Cancer Center | Phase 2 |